Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Foßelteder Johannes |
Präsentationen bei wissenschaftlichen und nicht-wissenschaftlichen Veranstaltungen
Alihodžić, D; Özkaya, E; Foßelteder, J; Sconocchia, T; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Wölfler, A; Vujić, N; Kratky, D; Reinisch, A
Investigating the contribution of TET2 mutant human clonal hematopoiesis to human atherosclerotic plaque formation in a novel LDLR/ApoE double knock-out mouse model.
Doctoral Day 2024; 08.02.2024; Graz, AUSTRIA. 2024.
[Poster]
Alihodžić, D; Özkaya, E; Foßelteder J; Sconocchia, T; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Wölfler A; Vujić, N; Kratky, D; Reinisch A
CRISPR/Cas9 genome engineering to model TET2 mutant human clonal hematopoiesis and its pro-atherogenic potential.
Austrian Atherosclerosis Society (AAS) Annual Meeting; MAI 2-4, 2024; St. Gilgen, AUSTRIA. 2024.
[Poster]
ALIHODŽIĆ, D; ÖZKAYA1, E; PABST, G; FOßELTEDER, J; SCONOCCHIA, T; AUINGER, L; SCHLENKE, P; SILL1, H; ZEBISCH, A; WÖLFLER, A; REINISCH, A
Modeling SRSF2/TET2 mutational cooperativity in CMML development
European Hematology Association (EHA) 2024 Hybrid Congress; JUNE 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Dutta, S; Rezania, S; Lyssy, F; Lind, K; Vosberg, S; Thallinger, G; Zebisch, A; Wölfler, A; Pabst, G; Foßelteder, J; Reinisch, A; Sill, H;
Deciphering the molecular mechanism of mesenchymal stromal cell mediated drug resistance in acute myeloid leukemia.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Foßelteder, J; Brauchart, T; Schlacher, A; Sconocchia, T; Özkaya, E; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Reinisch, A;
Engineered cytokine-expressing mesenchymal stromal cells support ex vivo culture of human HSPCs and AML cells.
BMS Future Talks; SEP 27-28, 2024; Vienna, AUSTRIA. 2024.
[Poster]
Foßelteder, J; Özkaya, E; Alihodžić, D; Raicht, A; Reinisch, A;
Genome Engineering to model human clonal hematopoiesis and myeloid leukemogenesis.
Experimental and Translational Hematology Meeting 2024; OCT 11-12, 2024; Krakow, POLAND. 2024.
[Oral Communication]
Foßelteder, J; Özkaya, E; Dorset, SR; Bak, RO; Reinisch, A;
DNA base editing to model hot spot mutations and reconstruct myeloid disease development.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN;. 2024.
[Poster]
FullText
Lind, K; Dutta, S; Foßelteder, J; Pabst, G; Reinisch, A; Wölfler, A; Zebisch, A; Sill, H;
Deciphering early steps of TP53 aberrant human leukemogenesis.
29th European Hematology Association Congress; JUN 13-16, 2024; Madrid, SPAIN. 2024.
[Poster]
Özkaya, E; Sconocchia, T; Foßelteder, J; Alihodzic, D;
Schlacher, A; Auinger, L; Schlenke, P; Sill, H; Zebisch, A; Reinisch, A
Genome engineered TET2 loss-of-function mutations increase stem cell self-renewal in human hematopoietic stem and progenitor cells.
Doctoral Day (DocDay); FEB 08 2024; Graz, Austria. 2024.
[Poster]
Galhuber, M; Michenthaler, H; Foßelteder J; Dutta, S; Reinisch, A; Krtic, J; Prokesch, A
Trp53 hotspot mutants’ response to HCC combination therapy
EMBO Workshop "Systems approaches in cancer"; JUN 26-30, 2023; Split, CROATIA. 2023.
[Poster]
Lyssy, F; Lind, K; Zöscher, F; Zebisch, A; Wölfler, A; Pabst, G; Fosselteder, J; Reinisch, A; Sill, H; Dutta, S
Modelling drug resistance conferred by mono- and bi-allelic TP53 aberrations using isogenic AML cell lines
ONCOL RES TREAT. 2023; 46: 188-189.
[Poster]
Web of Science
FullText
Pabst, G; Foßelteder, F; Schlacher, A; Auinger, L; Martinez-Krams, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, Ch; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A;
Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells.
Blood (2021) 138 (Supplement 1): 2160.. 2022; 138: 2160-2160.-ASH Annual Meeting 2021; DEZ 11-14, 2021; Atlanta, USA.
[Poster]
FullText
Foßelteder, J; Rosenberger, A; Pabst, G; Sill, H; Wölfler, A; Reinisch, A
Calreticulin mutations transform healthy hematopoietic stem cells into myeloproliferative neoplasms.
Doctoral Day 2021 at Medical University of Graz; FEB 12, 2021; Graz, AUSTRIA. 2021.
[Onlinepräsentation]
Foßelteder, J; Schlacher, A; Pabst, G; Amtmann, B; Schöll, W; Kashofer, K; Beham-Schmid, C; Schlenke, P; Greinix, HT; Sill, H; Woelfler, A; Zebisch, A; Reinisch, A
Introduction and Genetic Correction of Calreticulin Mutations in Human Hematopoietic Stem and Progenitor Cells Sheds Light on MPN Pathogenesis
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-147919
[Poster]
Web of Science
FullText
FullText_MUG
Klec, C; Seles, M; Fosselteder, J; Hutterer, GC; Slaby, O; Pichler, M
The Long non-coding RNA POU3F3 (PANTR1) as new player in clear cell renal cell carcinoma
Frühjahrstagung der ÖGHO. 2021; -Frühjahrstagung der ÖGHO; APR 8-10, 2021; Wien.
[Poster]
Pabst, G; Foßelteder, J; Schlacher, A; Auinger, L; Martinez-Krams3, D; Ediriwickrema, A; Kashofer, K; Beham-Schmid, C; Greinix, HT; Woelfler, A; Schlenke, P; Sill, H; Zebisch, A; Majeti, R; Reinisch, A
Modeling the Development of SRSF2 Mutated Myeloid Malignancies By CRISPR/Cas9 Mediated Genome Engineering of Primary Human Hematopoietic Stem and Progenitor Cells
Blood. 2021; 138(S1):-Annual Meeting of the American Society of Hematology (ASH); DEC 11-14, 2021; Atlanta, USA.
Doi: 10.1182/blood-2021-149591
[Poster]
Web of Science
FullText
FullText_MUG
Seles, M; Foßelteder, J; Zigeuner, RE; Pummer, K; Slaby, O; Klec, C; Pichler, M
Oncogenic functions of long non-coding RNA PANTR1 in clear-cell renal cell cancer
Doctoral Day 2021@Medical University of Graz; FEB 12,2021; Graz. 2021.
[Onlinepräsentation]
FullText
Tvorogov, D; Thompson-Peach, CAL; Fosselteder, J; Dottore, M; Stomski, F; Lim, KSY; Onnesha, SA; Ross, DM; Reinisch, A; Thomas, D; Lopez, AF
A Calreticulin Neoepitope-Directed Monoclonal Antibody Can Overcome JAK Inhibitor Resistance and Block TPO-Independent Megakaryocyte Differentation
BLOOD. 2021; 138:
Doi: 10.1182/blood-2021-154332
[Poster]
Web of Science
FullText
FullText_MUG
Seles, M; Hutterer, GC; Foßelteder, J; Bauernhofer, T; Zigeuner, R; Pummer, K; Slaby, O; Pichler, M; Klec, C
Aufschlüsselung der onkogenen Funktionen der langen nicht-kodierende RNA "PANTR1" beim klarzelligen Nierenzellkarzinom.
72. Jahrestagung der Deutschen Gesellschaft für Urologie; Sept 23-26; Leipzig, Online. 2020.
[Onlinepräsentation]
Seles, M; Hutterer, GC; Foßelteder, J; Svoboda, M; Resel, M; Barth, DA; Pichler, R; Bauernhofer, T; Zigeuner, RE; Pummer, K; Slaby, O; Klec, C; Pichler, M
Aufschlüsselung der onkogenen Funktionen der langen nicht-kodierende RNA "PANTR1" beim klarzelligen Nierenzellkarzinom.
72. Kongress der Deutschen Gesellschaft für Urologie; Sep, 14-26 2020; Hamburg, Germany/Virtuell. 2020.
[Onlinepräsentation]
Auinger, L; Rupp, V; Foßelteder, J; Frömmel, M; Geigl, J; Reinisch, A; Heitzer, E; Speicher, M;
Genetic Modelling of the BAP1 Tumour Predisposition Syndrome in Human iPSCs using an Inducible Knock-Out System
International Student Congress; MAI 31-JUNI 1, 2019; Medizinische Universität Graz. 2019.
[Poster]
FullText
Auinger, L; Rupp, V; Foßelteder, J; Reinisch, A; Geigl, J; Heitzer, E; Speicher, M;
How to Knock Out a Gene - the hard way
DocDay; NOV 21, 2019; Medizinische Universität Graz. 2019.
[Poster]
FullText
Foßelteder, J; Wölfler, A; Kargl, J; Schöll, W; Schlenke, P; Sill, H; Reinisch, A
In-vitro modeling of JAK2 V617F-driven myeloproliferative neoplasms
using CRISPR/Cas9 genome engineering.
DocDay 2019, Medical University of Graz; 21.11.2019; Graz, AUSTRIA. 2019.
[Poster]
Mosinzer, S; Foßelteder, J; Avdili, A; Schlenke, P; Reinisch, A
Generation of a TP53 isogenic cell line using CRISPR/Cas9 genome engineering
DocDay 2019, Medical University of Graz; Nov 21, 2019; Graz, AUSTRIA. 2019.
[Poster]
Seles, M; Foßelteder, J; Slaby, O; Klec, C; Mischinger, J; Hutterer, G; Pummer, K; Pichler, M
Identifikation und Charakterisierung einer neuen langen, nicht-kodierenden RNA RCA-lnc-RNA1 beim Nierenzellkarzinom
Der Urologe 2019, 58 (Suppl 1):S94/95.. 2019; -71. Kongress der Deutschen Gesellschaft für Urologie e.V.; SEP 18-21, 2019; Hamburg Messe, Deutschland.
[Oral Communication]
Seles, M; Foseltseder, J; Mischinger, J; Klec, C; Slaby, O; Hutterer, GC; Pummer, K; Zigeuner, R; Pichler, M.
Identification and characterization of a novel long non-coding RNA RCA-lncRNA1 in clear cell renal cell carcinoma
European Urology Supplements
. 2019; 18(2):e2349--CEM19: 19th Central European Meeting in conjunction with the Austrian Association of Urology and the Bavarian Society of Urology ; 2019-05-10; Vienna, Austria.
[Oral Communication]
FullText
Seles, M; Foseltseder, J; Mischinger, J;Klec, C; Slaby, O; Hutterer, GC, Zigeuner, R; Pummer, K; Pichler, M P
Identifikation und Charakterisierung der neuen langen,nicht-kodierenden RNA RCA-lnc-RNA1
German Medical Science GMS Publishing House; 2019. Doc19oegu091 . 2019; -45. Gemeinsame Tagung der Österreichischen Gesellschaft für Urologie und Andrologie und der Bayerischen Urologenvereinigung; MAY9-11 2019; Vienna, Austria.
[Oral Communication]
FullText
Klec, C; Resel, M; Foßelteder, J; Prinz, F; Kapeller, A; Deutsch, A; Heitzer, E; Rinner, B; Stöger, H; Graier, WF; Pichler, M
Paraspeckle-associated protein 1 (PAP1) controls breast cancer growth by regulating and interacting with the long non-coding RNA NEAT1.
Retrain the Brain. Doctoral Day 2018. 2018; -Doctoral Day 2018; NOV 28, 2018; Graz, AUSTRIA.
[Oral Communication]
Moritz, J; Tiran, V; Fosselteder, J; Stöger, H; Pichler, M; Dandachi, N;
Expression patterns and epigenetic regulation of immune-related genes in renal cell carcinoma
Frühjahrstagung OeGHO; April 19-21, 2018; Villach. 2018.
[Poster]